Phase 1b/2 trial of ribociclib plus binimetinib in metastatic NRAS-mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D).

被引：23
|
作者：
Schuler, Martin H.
Ascierto, Paolo A.
de Vos, Filip Yves Francine Leon
Postow, Michael Andrew
Van Herpen, Carla M. L.
Carlin, Matteo S.
Sosman, Jeffrey A.
Berking, Carola
Long, Georgina V.
Weise, Amy
Gutzmer, Ralf
Kaatz, Martin
McArthur, Grant A.
Schwartz, Gary
Daud, Adil
Maharry, Kati
Yerramilli-Rao, Padmaja
Zimmer, Lisa
Bozon, Viviana
Amaria, Rodabe Navroze
机构：
[1] Univ Hosp, West German Canc Ctr, Essen, Germany
[2] Ist Nazl Tumori Fdn G Pascale IRCCS, Naples, Italy
[3] Univ Med Ctr Utrecht, Canc Ctr, Dept Med Oncol, Utrecht, Netherlands
[4] Weill Cornell Med Coll, New York, NY USA
[5] Mem Sloan Kettering Canc Ctr, New York, NY USA
[6] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands
[7] Westmead & Blacktown Hosp, Sydney, NSW, Australia
[8] Melanoma Inst Australia, Sydney, NSW, Australia
[9] Northwestern Univ, Robert H Lurie Canc Ctr, Chicago, IL USA
[10] Univ Hosp Munich LMU, Dept Dermatol & Allergy, Munich, Germany
[11] Univ Sydney, Melanoma Inst Australia, Royal North Shore & Mater Hosp, Sydney, NSW, Australia
[12] Karmanos Canc Inst, Detroit, MI USA
[13] Hannover Med Sch, Skin Canc Ctr Hannover, Hannover, Germany
[14] SRH Wald Klinikum Gera GmbH, Gera, Germany
[15] Peter MacCallum Canc Ctr, Melbourne, Australia
[16] Columbia Coll Phys & Surg, New York, NY USA
[17] UCSF Helen Diller Family Comprehens Canc Ctr, Melanoma Clin Res, San Francisco, CA USA
[18] Array BioPharma Inc, Boulder, CO USA
[19] Novartis Inst BioMed Res, Cambrdige, MA USA
[20] Univ Texas MD Anderson Canc Ctr, Melanoma Med Oncol, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.9519
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9519
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma
    Schuler, Martin
    Zimmer, Lisa
    Kim, Kevin B.
    Sosman, Jeffrey A.
    Ascierto, Paolo A.
    Postow, Michael A.
    De Vos, Filip Y. F. L.
    van Herpen, Carla M. L.
    Carlino, Matteo S.
    Johnson, Douglas B.
    Berking, Carola
    Reddy, Micaela B.
    Harney, Allison S.
    Berlin, Jordan D.
    Amaria, Rodabe N.
    CLINICAL CANCER RESEARCH, 2022, 28 (14) : 3002 - 3010
  • [2] A phase 1b/2 study of ribociclib (LEE011; CDK4/6 inhibitor) in combination with binimetinib (MEK162; MEK inhibitor) in patients with NRAS-mutant melanoma
    Van Herpen, C.
    Postow, M. A.
    Carlino, M. S.
    Kalkavan, H.
    Weise, A.
    Amaria, R. N.
    De Vos, F.
    Carvajal, R. D.
    Matano, A.
    Bhansali, S.
    Lam, L.
    Yerramilli-Rao, P.
    Sosman, J. A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S663 - S663
  • [3] The IRX-2 regimen combined with nivolumab in recurrent/metastatic solid tumors: A phase 1b study to evaluate the safety, determine recommended phase 2 dose (RP2D), and investigate the biologic and clinical activity.
    Jain, Rohit K.
    Zhang, Jingsong
    Eroglu, Zeynep
    Creelan, Ben C.
    Brohl, Andrew Scott
    Shafique, Michael Rahman
    Gray, Jhanelle Elaine
    Muzaffar, Jameel
    Ida, Julia
    Lacevic, Mensura
    Kim, Youngchul
    Chung, Christine H.
    Sahebjam, Solmaz
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] ACCLAIM-1 dose escalation: Determination of quaratusugene ozeplasmid and osimertinib recommended phase 2 dose (RP2D).
    Berz, David
    Jotte, Robert M.
    Pachipala, Krishna Kishore
    Spira, Alexander I.
    Berger, Mark S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2.
    Hamid, Omid
    Liu, Stephen V.
    Boccia, Ralph V.
    Call, Justin A.
    Wise-Draper, Trisha Michel
    Alistar, Angela Tatiana
    Powderly, John D.
    Carthon, Bradley Curtis
    Vaishampayan, Ulka N.
    Olszanski, Anthony J.
    Wrangle, John M.
    Shields, Anthony Frank
    Piha-Paul, Sarina Anne Anne
    Desai, Monali
    Du, Yangchun
    Sun, Lei
    Wang, Yan
    Losey, Heather
    Hopkinson, Craig
    Ernstoff, Marc S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity.
    Sosman, Jeffrey Alan
    Kittaneh, Muaiad
    Lolkema, Martijn P. J. K.
    Postow, Michael Andrew
    Schwartz, Gary
    Franklin, Catherine
    Matano, Alessandro
    Bhansali, Suraj
    Parasuraman, Sudha
    Kim, Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Mitazalimab (CD40 agonist) in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Safety data and recommended dose for phase 2 (RP2D) from OPTIMIZE-1, a phase 1b/2 study.
    Van Laethem, Jean-Luc
    Borbath, Ivan
    Prenen, Hans
    Lambert, Aurelien
    Geboes, Karen
    Blanc, Jean-Frederic
    de Coana, Yago Pico
    Enell-Smith, Karin
    Schultz, Lena
    Nordbladh, Karin
    Ellmark, Peter
    Ambarkhane, Sumeet
    Carlsson, Malin
    Cassier, Philippe
    CANCER RESEARCH, 2022, 82 (22) : 10 - 11
  • [8] Safety and Recommended Phase II Dose (RP2D) of the Selective Oral MEK1/2 Inhibitor Pimasertib (MSC1936369B/AS703026): Results of a Phase I Trial
    Awada, A.
    Delord, J. P.
    Houede, N.
    Lebbe, C.
    Lesimple, T.
    Schellens, J. H. M.
    Rottey, S.
    Kefford, R.
    Rejeb, N.
    Raymond, E.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 185 - 186
  • [9] Tepotinib plus gefitinib in patients with c-Met-positive/EGFR-mutant NSCLC: Recommended phase II dose (RP2D), tolerability, and efficacy
    Wu, Y-L.
    Soo, R.
    Kim, D-W.
    Yang, J.
    Stammberger, U.
    Chen, W.
    Locatelli, G.
    Park, K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [10] Tolerability, efficacy and recommended phase II dose (RP2D) of tepotinib plus gefitinib in Asian patients with c-Met-positive/EGFR-mutant NSCLC: Phase Ib data.
    Wu, Yi-Long
    Soo, Ross A.
    Kim, Dong-Wan
    Yang, James Chih-Hsin
    Stammberger, Uz M.
    Chen, Wenfeng
    Johne, Andreas
    Park, Keunchil
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345